Who makes BHT-3009-01?

BHT-3009-01 is developed by Bayhill Therapeutics.

Last reviewed 2026-04-20 · How we verify

BHT-3009-01

Bayhill Therapeutics · Phase 1 active Biologic Quality 0/100

At a glance

Generic name	BHT-3009-01
Sponsor	Bayhill Therapeutics
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BHT-3009-01 CI brief — competitive landscape report
BHT-3009-01 updates RSS · CI watch RSS
Bayhill Therapeutics portfolio CI